BioSante Pharmaceuticals has announced that Dr. Steve Bell, vice president of research and pre-clinical development for BioSante, will present a review of progress with BioVant(TM), the company's patented calcium phosphate (CaP) nanoparticle technology, at the Second International Conference on Immunopotentiators in Modern Vaccines (IMV 2005) meeting in Malaga, Spain. The presentation entitled, "Calcium Phosphate Nanoparticles versus Microparticles: Selective Th1 versus Th2 Immunity," will take place Thursday, May 19 at 9:30 a.m. CEST (3:30 a.m. ET).
Dr. Bell will provide a review of progress toward the use of BioVant for "rational vaccine design." Based upon careful analysis of immune response results in pre-clinical testing using BioVant in bacterial and viral vaccine candidates, the presentation will include a conceptualization of the functional efficacy of BioVant, which highlights its use to selectively elicit Th1 or Th2 T-helper immunity. This approach may lead to the ability to rapidly create highly specialized vaccines for emerging viruses and bioterrorism applications.
http://www.biosantepharma.com
Posted 19th May 2005
